

# Studienverzeichnis Tumor Zentrum Aarau

Frühere klinische Studien, die am Tumor Zentrum Aarau  
durchgeführt worden sind

# Brustkrebs (1/3)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
SAKK 24/06	II	Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial.	2008	1
IBCSG 24/02 - SOFT	III	A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer	2011	2
SAKK 24/09	III	Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial	2012	3
TANIA - MO22998	III	A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment	2015	3

# Brustkrebs (2/3)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
IBCSG 22/00	III	Low-dose Cytotoxics as "Anti-angiogenesis Treatment" following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer	2016	9
SAKK 22/10	II	A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer	2016	1
3144A2 3005	II	A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer	2018	1
IBCSG 35/07 SOLE	III	A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer	2018	8
MonaLEESA7	III	A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer	2019	2

# Brustkrebs (3/3)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
3144A2-3004-WW / B1891004	III	A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer	2019	5
MonaLEESa3	III	MONALEESA-3: A randomized double-blind, placebocontrolled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment	2020	3
SafeHer - MO28048	III	A phase III prospective two-cohort nonrandomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable HER2-positive early breast cancer [SafeHer Study]	2020	5

# Urologische Tumoren

Studie	Phase	Beschreibung	Studien-Ende	Patienten
Seqond	Registry	QoL in 2nd line therapy	2015	10
TAK-700 - C21004	III	A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer	2016	4
212082PCR4001	Registry	A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer	2018	15
Stampede	II/III	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy A multi-arm multi-stage randomised controlled trial	Follow-up	3

# Gastrointestinale Tumoren (1/2)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
SAKK 41/03	I/II	Oxaliplatin, irinotecan and capecitabine as a combination regimen for first line reatment of advanced or metastatic colorectal cancer. A multicenter phase I-II trial	2007	1
SAKK 76/02	II	Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery	2010	1
SAKK 41/07	II	Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial	2010	1
SAKK 41/06	III	Bevacizumab maintenance versus no maintenance after stop of first-line chemotherapy in patients with metastatic colorectal cancer. A randomized multicenter phase III non-inferiority trial.	2012	9
ML18147	III	A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease progression under first-line standard CTx / Bevacizumab combination.	2013	2

# Gastrointestinale Tumoren (2/2)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
MAVERICC ML25710	II	A randomized Phase II study of Bevacizumab/mFOLFOX6 vs Bevacizumab/mFOLFOFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer	2015	2
QuoliTrap	IV	Beobachtungsstudie zur Erfassung der Lebensqualität bei Patienten mit metastasiertem kolorektalem Karzinom unter Zaltrap® Therapie (QoLiTrap)	Follow up	1
I4T-MC-JVDD	IV	Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry	Follow up	7

# Lunge

Studie	Phase	Beschreibung	Studien-Ende	Patienten
NEXT - EMR 062 240-506	IIIb	Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m <sup>2</sup> weekly and 500 mg/m <sup>2</sup> every two weeks maintenance therapy after platinum-based chemotherapy in combination with cetuximab as first-line treatment for subjects with advanced non-small cell lung cancer (NSCLC)	2013	2
M11-089	III	Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)	2018	2



# Diverse Indikationen (1/2)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
START		Swiss Taxotere Alopecia Prevention Trial	2011	9
BEVLIN - MO21609	II	An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma	2012	1
SOMPAS - 20070626		A prospective non-interventional evaluation of the management of symptomatic anemia in patients receiving myelotoxic chemotherapy for colorectal cancer, breast cancer and lung cancer in Switzerland	2013	4
Proskin		Prospective, observational practice survey of applied skin care and management of Cetuximab related skin reactions	2015	5
MENAC		A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing chemotherapy.	2019	3
SAKK 35/14	II	Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.	Follow up	1

# Diverse Indikationen (2/2)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
FN01 MASCC Survey	Observational	Predicting febrile neutropenia occurrence in adult patients treated with chemotherapy for a solid tumor (or a Hodgkin's/non-Hodgkin's lymphoma) with an expected moderate risk of febrile neutropenia according to published guidelines (10% to 20%): a MASCC survey	2020	12
Consilium	Observational	Efficiency of the "Consilium" smartphone app for detecting symptoms and treatment side effects in cancer patients depending on form of medication application, age and outpatient characteristics: observational study	2020	15